Targeted therapies for small cell lung cancer: Where do we stand?

摘要: Small cell lung cancer (SCLC) accounts for 15% of cases and is associated with a dismal prognosis. Standard therapeutic regimens have been improved over the past decades, but without major impact on patient survival. The development targeted therapies based better understanding molecular basis disease urgently needed. At genetic level, SCLC appears very heterogenous, although somatic mutations targeting classical oncogenes tumor suppressors reported. also possesses in many other genes, including transcription factors, enzymes involved chromatin modification, receptor tyrosine kinases their downstream signaling components. Several avenues explored to develop SCLC. So far, however, there has limited success these approaches clinical trials. Further progress optimization will require more personalized patients.